JP2010518125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518125A5 JP2010518125A5 JP2009549295A JP2009549295A JP2010518125A5 JP 2010518125 A5 JP2010518125 A5 JP 2010518125A5 JP 2009549295 A JP2009549295 A JP 2009549295A JP 2009549295 A JP2009549295 A JP 2009549295A JP 2010518125 A5 JP2010518125 A5 JP 2010518125A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- aralkyl
- aryl
- solution
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 40
- 239000000243 solution Substances 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 33
- 230000000694 effects Effects 0.000 claims 29
- 238000000034 method Methods 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000003710 aryl alkyl group Chemical group 0.000 claims 20
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 20
- 108091006112 ATPases Proteins 0.000 claims 18
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 18
- 239000003550 marker Substances 0.000 claims 16
- -1 -C (O) H Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims 6
- 229920004890 Triton X-100 Polymers 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 6
- 229920000728 polyester Polymers 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 5
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical group CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 108060004795 Methyltransferase Proteins 0.000 claims 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000000758 substrate Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 claims 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920001992 poloxamer 407 Polymers 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 108700004121 sarkosyl Proteins 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000012089 stop solution Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- LZTSCEYDCZBRCJ-UHFFFAOYSA-N 1,2-dihydro-1,2,4-triazol-3-one Chemical compound OC=1N=CNN=1 LZTSCEYDCZBRCJ-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- ZRKZFNZPJKEWPC-UHFFFAOYSA-N decylamine-N,N-dimethyl-N-oxide Chemical compound CCCCCCCCCC[N+](C)(C)[O-] ZRKZFNZPJKEWPC-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- YYRMITYYFKZLLJ-UHFFFAOYSA-N n,n-dimethylhexan-1-amine oxide Chemical group CCCCCC[N+](C)(C)[O-] YYRMITYYFKZLLJ-UHFFFAOYSA-N 0.000 claims 1
- XZEZLJBGDNUAQX-UHFFFAOYSA-N n,n-dimethylnonan-1-amine oxide Chemical compound CCCCCCCCC[N+](C)(C)[O-] XZEZLJBGDNUAQX-UHFFFAOYSA-N 0.000 claims 1
- RSVIRMFSJVHWJV-UHFFFAOYSA-N n,n-dimethyloctan-1-amine oxide Chemical compound CCCCCCCC[N+](C)(C)[O-] RSVIRMFSJVHWJV-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88943307P | 2007-02-12 | 2007-02-12 | |
| PCT/US2008/053617 WO2008100867A2 (en) | 2007-02-12 | 2008-02-11 | Novel inhibitors hepatitis c virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518125A JP2010518125A (ja) | 2010-05-27 |
| JP2010518125A5 true JP2010518125A5 (enExample) | 2011-03-31 |
Family
ID=39590457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549295A Pending JP2010518125A (ja) | 2007-02-12 | 2008-02-11 | Ｃ型肝炎ウイルス複製の新規な阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090047246A1 (enExample) |
| EP (1) | EP2134683A2 (enExample) |
| JP (1) | JP2010518125A (enExample) |
| CN (1) | CN101687789A (enExample) |
| AU (1) | AU2008216382A1 (enExample) |
| CA (1) | CA2676906A1 (enExample) |
| MX (1) | MX2009008439A (enExample) |
| WO (1) | WO2008100867A2 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| BRPI0617271A2 (pt) * | 2005-10-11 | 2011-07-19 | Intermune Inc | inibidores de replicação viral |
| CN102850324A (zh) | 2006-08-07 | 2013-01-02 | 硬木药品公司 | 吲哚化合物 |
| CA2683821A1 (en) * | 2007-05-02 | 2008-11-13 | Novartis Ag | Heterocyclic compounds and their use as pesticides |
| WO2008136948A1 (en) | 2007-05-07 | 2008-11-13 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| JP5249344B2 (ja) * | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | ヘテロ環の３位が置換されたインドール誘導体およびその使用 |
| CN101910145A (zh) * | 2008-02-14 | 2010-12-08 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
| US8367671B2 (en) | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US9301949B2 (en) * | 2009-02-27 | 2016-04-05 | Siga Technologies, Inc. | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
| MX2011010058A (es) | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| GB0906026D0 (en) * | 2009-04-07 | 2009-05-20 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| SG177384A1 (en) | 2009-06-29 | 2012-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
| WO2011014128A1 (en) * | 2009-07-30 | 2011-02-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
| SI2462119T1 (sl) * | 2009-08-03 | 2014-10-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Postopek za pripravo 1-benzil-3-hidroksimetil-1H-indazola in njegovih derivatov ter potrebni magnezijevi intermediati |
| WO2011049988A2 (en) * | 2009-10-20 | 2011-04-28 | Eiger Biopharmaceuticals, Inc. | Indazoles to treat flaviviridae virus infection |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| US8354410B2 (en) * | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
| JP5816678B2 (ja) | 2010-04-14 | 2015-11-18 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | ＰＩ３Ｋδ阻害剤としての縮合誘導体 |
| CN103601683B (zh) * | 2010-04-16 | 2016-03-30 | 中国科学院上海药物研究所 | 苯并杂环类化合物及其制备方法和用途 |
| AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| RS54742B1 (sr) | 2010-05-17 | 2016-10-31 | Forum Pharmaceuticals Inc | Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| US20130302282A1 (en) | 2010-10-26 | 2013-11-14 | Presidio Pharmaceuticals, Inc. | Inhibitors of Hepatitis C Virus |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| EP2508511A1 (en) * | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP3552664A1 (en) * | 2011-05-12 | 2019-10-16 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| MY179332A (en) | 2011-09-02 | 2020-11-04 | Incyte Holdings Corp | Heterocyclylamines as pl3k inhibitors |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US9585877B2 (en) | 2012-05-08 | 2017-03-07 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| RU2014152790A (ru) | 2012-06-20 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пирролопиразоновые ингибиторы танкиразы |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| US9394285B2 (en) | 2013-03-15 | 2016-07-19 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| PT2970265T (pt) * | 2013-03-15 | 2018-10-23 | Plexxikon Inc | Compostos heterocíclicos e suas utilizações |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| HRP20201621T1 (hr) | 2014-04-04 | 2021-03-05 | Iomet Pharma Ltd. | Derivati indola za uporabu u medicini |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| WO2015195486A1 (en) | 2014-06-20 | 2015-12-23 | The University Of North Carolina At Greensboro | Beta-arrestin-biased cannabinoid cb1 receptor agonists and methods for making and using them |
| US10329306B2 (en) | 2014-09-29 | 2019-06-25 | Takeda Pharmaceutical Company Limited | Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide |
| DK3203840T3 (da) | 2014-10-06 | 2020-08-31 | Vertex Pharma | Modulatorer af cystisk fibrose-transmembrankonduktansregulator |
| EP3831833B1 (en) | 2015-02-27 | 2022-10-26 | Incyte Holdings Corporation | Processes for the preparation of a pi3k inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2017030938A1 (en) * | 2015-08-14 | 2017-02-23 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| CN105348181B (zh) * | 2015-12-16 | 2018-02-13 | 辽宁工程技术大学 | 一种2‑氨基‑5‑甲基‑6‑溴吡啶的制备方法 |
| CA3010615C (en) | 2016-01-14 | 2024-02-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| ES2946970T3 (es) | 2016-03-31 | 2023-07-28 | Vertex Pharma | Regulador de conductancia transmembrana de moduladores de fibrosis quística |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| MD3551622T2 (ro) | 2016-12-09 | 2021-03-31 | Vertex Pharma | Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului |
| FI3609868T3 (fi) | 2017-03-13 | 2023-11-22 | Raqualia Pharma Inc | Tetrahydrokinoliinijohdannaisia P2X7-reseptorin antagonisteina |
| WO2018191418A1 (en) | 2017-04-11 | 2018-10-18 | Saje Pharma, Llc | Carbazole compounds and methods of use thereof |
| WO2018227049A1 (en) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| MA50400A (fr) | 2017-10-19 | 2020-08-26 | Vertex Pharma | Formes cristallines et compositions de modulateurs de cftr |
| UA126592C2 (uk) * | 2017-10-25 | 2022-11-02 | Байєр Фарма Акцієнгезелльшафт | Спосіб одержання бензотіофен-2-ілборонату |
| CN107805244B (zh) * | 2017-11-14 | 2018-08-03 | 牡丹江医学院 | 一种用于治疗乙型肝炎的药物及其制备方法 |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| AU2019277560B2 (en) | 2018-06-01 | 2025-04-24 | Incyte Corporation | Dosing regimen for the treatment of PI3K related disorders |
| WO2020006152A1 (en) * | 2018-06-26 | 2020-01-02 | Northeastern University | N-substituted indoles and use as allosteric modulators of cannabinoid receptors |
| RU2019123849A (ru) * | 2019-07-29 | 2021-02-01 | Дзе Брихэм Энд Уимен`З Хоспитал, Инк. | Ингибиторы фактора ингибирования миграции макрофагов |
| CN110526848B (zh) * | 2019-09-04 | 2020-09-08 | 青岛农业大学 | 分子间氢迁移引发环胺β-C(sp3)–H官能化合成β-取代的吡咯烷类化合物的方法 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| US20230255933A1 (en) * | 2020-07-06 | 2023-08-17 | Crescenta Biosciences | Antiviral use of fabp4 modulating compounds |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3134663A (en) * | 1957-07-23 | 1964-05-26 | Geigy Chem Corp | Herbicidal composition and method employing hydantoins |
| US3448116A (en) * | 1966-04-25 | 1969-06-03 | American Home Prod | Preparation of 1-hydroxyhydantoins and 1-hydroxythiohydantoins |
| US3494932A (en) * | 1967-06-26 | 1970-02-10 | American Cyanamid Co | Aminoalkyl substituted aryl hydantoins |
| US3948939A (en) * | 1970-06-02 | 1976-04-06 | Sterling Drug Inc. | 9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids |
| JPS5136332B1 (enExample) * | 1970-12-09 | 1976-10-07 | ||
| CH544491A (de) * | 1971-03-16 | 1973-11-30 | Ciba Geigy Ag | Herbizides Mittel |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| US4536505A (en) * | 1983-05-17 | 1985-08-20 | Ciba-Geigy Corporation | Certain N-(pyridyl) indoles |
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| CA2605872A1 (en) * | 1992-12-29 | 1994-06-30 | Abbott Laboratories | Intermediates for retroviral protease inhibiting compounds |
| US6090822A (en) * | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| US6232333B1 (en) * | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US7256005B2 (en) * | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| EP1362047B1 (en) * | 2000-12-08 | 2006-05-17 | Ortho-McNeil Pharmaceutical, Inc. | Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| AR035543A1 (es) * | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2003212846A (ja) * | 2001-06-26 | 2003-07-30 | Japan Tobacco Inc | 縮合環化合物及びｃ型肝炎治療剤 |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| MXPA05004608A (es) * | 2002-11-01 | 2005-09-20 | Viropharma Inc | Compuestos de benzofurano, composiciones y metodos para tratamiento de profilaxis de infecciones virales de hepatitis c y enfermedades asociadas. |
| GB0307891D0 (en) * | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| US7199125B2 (en) * | 2003-10-02 | 2007-04-03 | Bristol-Myers Squibb Company | Spiro-cyclic compounds useful as anti-inflammatory agents |
| WO2005112640A2 (en) * | 2004-05-13 | 2005-12-01 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| GB0413087D0 (en) * | 2004-06-11 | 2004-07-14 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2573185A1 (en) * | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| TW200616634A (en) * | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
| JP2008515805A (ja) * | 2004-10-04 | 2008-05-15 | ミリアド ジェネティクス， インコーポレイテッド | アルツハイマー病のための化合物 |
| JP2008520674A (ja) * | 2004-11-22 | 2008-06-19 | スミスクライン ビーチャム コーポレーション | Ｈｃｖインヒビター |
| MX2007008587A (es) * | 2005-01-14 | 2007-09-07 | Genelabs Tech Inc | Derivados de indol para tratamiento de infecciones virales. |
| JP2008543780A (ja) * | 2005-06-10 | 2008-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイド模倣薬、それらの製造方法、医薬組成物及びそれらの使用 |
| WO2007011626A2 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| BRPI0617271A2 (pt) * | 2005-10-11 | 2011-07-19 | Intermune Inc | inibidores de replicação viral |
| ES2386462T3 (es) * | 2005-10-28 | 2012-08-21 | Boehringer Ingelheim International Gmbh | Ensayo de la actividad NS2/3 del virus de la hepatitis C |
| UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
| US20070141701A1 (en) * | 2005-12-21 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Hepatitis c virus ns2/3 assay |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
-
2008
- 2008-02-11 CA CA002676906A patent/CA2676906A1/en not_active Abandoned
- 2008-02-11 AU AU2008216382A patent/AU2008216382A1/en not_active Abandoned
- 2008-02-11 WO PCT/US2008/053617 patent/WO2008100867A2/en not_active Ceased
- 2008-02-11 EP EP08729562A patent/EP2134683A2/en not_active Withdrawn
- 2008-02-11 CN CN200880010161A patent/CN101687789A/zh active Pending
- 2008-02-11 JP JP2009549295A patent/JP2010518125A/ja active Pending
- 2008-02-11 US US12/029,399 patent/US20090047246A1/en not_active Abandoned
- 2008-02-11 MX MX2009008439A patent/MX2009008439A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518125A5 (enExample) | ||
| JP2013538230A5 (enExample) | ||
| JP2014503516A5 (enExample) | ||
| JP2013514359A5 (enExample) | ||
| Jin et al. | Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors | |
| JP2013521279A5 (enExample) | ||
| WO2021075147A1 (ja) | Ｂｒａｐ２作用増強剤 | |
| EP4548977A2 (en) | Novel isoquinolines as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives | |
| UA121468C2 (uk) | Амідні сполуки, способи одержання, застосування як засобів для лікування й профілактики захворювань, що викликаються рнк- і/або днк-вмісними вірусами, й супутніх захворювань | |
| Xu et al. | Discovery of novel substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent human adenovirus inhibitors | |
| KR101868128B1 (ko) | 인플루엔자 a rna-의존성 rna 폴리머라제의 저분자 저해제 | |
| Nandi et al. | Repurposing of drugs and HTS to combat SARS-CoV-2 main protease utilizing structure-based molecular docking | |
| JP2014517847A (ja) | エプスタイン・バー核抗原１の活性を調節する組成物および方法 | |
| WO2009119167A1 (ja) | 抗ｒｎａウイルス作用を有するアニリン誘導体 | |
| CN101268081B (zh) | 5,6-二甲基噻吩并[2,3-di]嘧啶衍生物，其制备方法和用于抗病毒的包含其的药物组合物 | |
| JP2022509763A (ja) | アレナウイルス感染症の治療のための化合物 | |
| EP4074314A1 (en) | Isoquinoline derivatives for use as antiviral and antitumour agents | |
| JP7569433B2 (ja) | 抗ウイルス剤としてのピロリジンメインプロテアーゼ阻害剤 | |
| EP2028938A1 (en) | 3,4-disubstituted coumarin and quinolone compounds | |
| CA2790294C (en) | .alpha.-crystalline form of carbabenzpyride | |
| AU2023363824A1 (en) | Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives | |
| KR101567558B1 (ko) | Ｃ형 간염 바이러스의 게놈 복제의 선택적 저해 활성을 갖는 인돌계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물 | |
| JP2013189413A (ja) | 抗ウイルス組成物 | |
| JP2017518379A (ja) | 複素環化合物及びその使用方法 | |
| WO2002053550A1 (en) | Benzofuran derivatives and pharmaceutical compositions containing the same |